Cart
sales@molnova.com
BAY-545
CAS No. 1699717-32-2
BAY-545( —— )
Catalog No. M21950 CAS No. 1699717-32-2
BAY-545 is an antagonist of A2B adenosine receptor(IC50 : 59 nM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 181 | In Stock |
|
| 5MG | 164 | In Stock |
|
| 10MG | 247 | In Stock |
|
| 25MG | 444 | In Stock |
|
| 50MG | 625 | In Stock |
|
| 100MG | 870 | In Stock |
|
| 200MG | 1172 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBAY-545
-
NoteResearch use only, not for human use.
-
Brief DescriptionBAY-545 is an antagonist of A2B adenosine receptor(IC50 : 59 nM).
-
DescriptionBAY-545 is an antagonist of A2B adenosine receptor(IC50 : 59 nM).
-
In VitroBAY-545 is selective at A2B adenosine receptor over A1, A2A, and A3 adenosine receptor, with IC50s of 1300 nM (Human A1 adenosine receptor), 820 nM (Human A2A adenosine receptor), 470 nM (Mouse A2A adenosine receptor) and 750 nM (Rat A2A adenosine receptor).
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetAdenosine Receptor
-
RecptorA2B?adenosine receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1699717-32-2
-
Formula Weight433.45
-
Molecular FormulaC18H22F3N3O4S
-
Purity>98% (HPLC)
-
SolubilityDMSO:145 mg/ml(334.53 mM)
-
SMILESCCn1c(=O)n(CCC(F)(F)F)c2sc(C(=O)N3CCC(O)CC3)c(C)c2c1=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.H?rter M, et al. Novel non-xanthine antagonist of the A2B adenosine receptor: From HTS hit to lead structure. Eur J Med Chem. 2019 Feb 1;163:763-778.
molnova catalog
related products
-
DPCPX
DPCPX is an A1 adenosine receptor antagonist
-
Penbutolol sulfate
Penbutolol sulfate is able to bind to both β2-adrenergic receptor and β1-adrenergic receptor, thus making it a non-selective β blocker.
-
CI-947
An orally active adenosine receptor agonist that can induce acute cardiovascular toxicity and coronary vascular injury in vivo.
